VANCOUVER, BC, Dec. 2, 2025 /CNW/ - BirchBioMed Inc., a leading clinical stage biopharmaceutical company, expert in the development of products for scarring and other fibrosis-related disorders and ...

FDA has granted orphan drug designation to FS2 (kynurenic acid) for the investigational treatment of idiopathic pulmonary ...

Non-Cystic Fibrosis Bronchiectasis Treatment Market to Reach USD 3.5 Bn by 2035 at 5.8% CAGR, Driven by rising disease burden ...

Nerandomilast, a PDE4B inhibitor, is a new treatment option for IPF, showing better tolerability than nintedanib and ...

Propanc Biopharma Inc (NASDAQ:PPCB) rose 5.4% on Monday after announcing it has applied for a foreign filing license in Spain ...

Therapeutics Market Size accelerated to USD 10.60 billion in 2024, up from USD 9.22 billion in 2023, and is now projected to expand aggressively to USD 35.09 billion by 2033, recording a CAGR of 14.2% ...

Cystic fibrosis remains an incurable genetic disorder which impairs lung function and significantly reduces life expectancy. A new combination drug therapy which addresses the disorder's underlying ...

"It's not a cure, but it's the closest thing we have," a doctor said. "Imagine waiting 28 years for a miracle, and then it suddenly happens." That's how Gunnar Esiason, a 28-year-old graduate student ...

An easy-to-administer electrolyte test could offer new insight into response to treatment and disease progression for patients with cystic fibrosis. In a new study, researchers found that urine ...

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The ...

From 2008 to 2023, there has been a significant decrease in cystic fibrosis mortality rates and a significant rise in sickle ...

At the Liver Meeting sponsored by the American Association for the Study of Liver Diseases, investigators presented new ...